Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > March 2014 - Volume 25 - Issue 3 > Metastatic castration-resistant prostate cancer: changing l...
Text sizing:
A
A
A
Anti-Cancer Drugs:
doi: 10.1097/CAD.0000000000000045
Review Article

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel

Fernández, Ovidioa; Afonso, Javierb; Vázquez, Sergioe; Campos, Begoñae; Lázaro, Matínf; León, Luisc; Antón Aparicio, Luis M.d

Collapse Box

Abstract

Docetaxel is the standard first-line chemotherapy for men with metastatic castration-resistant prostate cancer. Until recently, there was no standard therapy after failure of docetaxel treatment. Cabazitaxel has been shown to improve overall survival in this setting. As a result, the treatment paradigm for mCRPC is changing rapidly. The improved survival shown with cabazitaxel provides an important new opportunity to treat men with mCRPC after docetaxel treatment. Despite the toxicity recorded in the pivotal study, subsequent trials have shown that cabazitaxel is a safe drug. Patient selection and the optimal interval between prior docetaxel treatment and cabazitaxel remain the critical issues. According to a subanalysis of the various studies discussed in this review, there is a patient profile that will probably benefit from use of cabazitaxel after docetaxel failure. Cabazitaxel represents a new treatment option for patients with prostate cancer.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.